Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA.
Chavan SS, et al. Among authors: stephens p, stephens o.
Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12.
Blood Cancer J. 2017.
PMID: 28234347
Free PMC article.